ADC Cytotoxic Payloads / Warheads Market: Products and Services Market, 2021-2035

ADC Cytotoxic Payloads / Warheads Market: Products and Services Market, 2021-2035

With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 300 candidates in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) have emerged as a promising class of therapeutics for the treatment of various disease indications. Over time, medical researchers have been able to further develop their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. Given the fact that ADCs are highly potent cytotoxic molecules, the manufacturing of these conjugated entities requires elaborate technical capabilities and highly potent chemical substances. Specifically, the multi-step process of production of cytotoxic payloads, which are used in ADCs, requires a contained environment, dedicated manufacturing facilities, specialized analytical and purification techniques, and storage facilities. However, several ADC developers do not have the in-house capabilities to manufacture cytotoxic payload on a commercial scale and tend to rely on contract manufacturers. As per the estimates, 70-80% of ADC manufacturing operations are outsourced.

Since 2000, several contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs), offering HPAPI and cytotoxic drug related services have been established to cater to the rise in demand of cytotoxic payloads in ADCs and other similar therapeutic interventions. In addition, several ADC developers have forged strategic partnerships with payload providers to advance the development of pipeline ADC candidates. Given the growing clinical pipeline of ADCs, coupled to the various technological advancements, the market for ADC payloads and warheads is anticipated to witness substantial growth in the coming years.

The “ADC Cytotoxic Payloads / Warheads Products and Services Market: Distribution by Type of Product (Commercialized ADCs and Clinical ADCs), Type of Payload (Microtubule Inhibitors, DNA Damaging Agents, Topoisomerase Inhibitors and Others), Payload / Warhead (Auristatins, Calicheamicin, Camptothecin, Duocarmycin, Maytansinoids, Pyrrolobenzodiazepines and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World)” report offers a comprehensive study of the current and future opportunity within the ADC payloads and warheads market. The study features an in-depth analysis, highlighting the capabilities of developers / contract services providers engaged in this domain. In addition to other elements, the study includes:

A review of the overall market landscape of the companies offering ADC payloads and warheads, featuring a detailed analysis based on the type of payload, type of microtubule inhibitors, DNA damaging agents and toposimerase inhibitors. In addition, it includes information on the developer’s year of establishment, and location of headquarters and company size of the players.

Elaborate profiles of players involved in the manufacturing of ADC payloads and warheads. Each profile features a brief overview of the company, its facility location, its financial information (if available), recent developments, and an informed future outlook.

An analysis of the partnerships that have been established in this domain since 2016, covering instances of licensing agreements, R&D agreements, mergers / acquisitions, manufacturing and supply agreements, product development agreements, service alliance, product development and commercialization agreements, and other relevant types of deals.

An analysis of the investments made, including seed funding, venture capital financing, debt funding, grants, capital raised from IPOs and subsequent offerings, at various stages of development, in companies focused on the development of ADC payloads and warheads.

A review of the expansions that have undertaken by the players engaged in developing ADC payloads and warheads for enhancing their respective offerings. It features a detailed analysis based on a number of parameters, including year of expansion, type of expansion (capacity expansion, facility expansion and new facility), location of facility and leading players.

An in-depth analysis of the various patents that have been filed / granted related to ADC payloads and warheads, highlighting key trends across the parameters, such as publication year, patent type, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry players (in terms of size of intellectual property portfolio). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.

An informed estimate of the annual clinical / commercial demand for ADC paylaods and warheads (in kilograms), taking into account parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

A case study on the ADCs that are already approved and those that are under development (clinical and preclinical), providing information on their phase of development (approved, clinical and preclinical / discovery stage), therapeutic area, line of treatment, dosing regimen, target antigen, antibody isotype, type of linker, type of payload / warhead and type of payload category. In addition, it provides a list of ADC developers, along with information on their year of establishment, company size and geography. The chapter also highlights the key players (in terms of number of drugs developed) in this industry.

A case study on the ADC contract manufacturing market, highlighting a list of contract service providers and in-house manufacturers that are currently active in this space. The chapter includes a detailed review of the overall landscape of companies offering contract services for the manufacturing of ADCs, along with information on the type of service offered, other services offered, scale of operation (preclinical, clinical and commercial) and location of manufacturing facilities.

One of the key objectives of this report was to evaluate the existing market size and the future potential of the ADC payloads and warheads market in the mid to long term. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of payload (microtubule inhibitors, DNA damaging agents, topoisomerase inhibitors and Others) [B] payload / warhead (maytansinoids, auristatins, camptothecins, maytansinoids, pyrrolobenzodiazepines, calicheamicin, duocarmycin and Others), [C] type of product (clinical and commercial ADC) and [D] key geographies (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the anticipated industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

Kevin Daley (Market Director, Novasep)
Floris Van Delft (Founder and Chief Scientific Officer, Synaffix)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been primarily gathered via primary and secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market insights gathered from various secondary and primary sources of information.

KEY QUESTION ANSWERED
Who are the leading players engaged in the development of ADC payloads and warheads?
Which partnership models are commonly adopted by stakeholders in this field?
What are the investment trends in this industry?
What are the key regions targeted by contract manufacturers for expanding or setting up of new facilities?
What is the current global demand for ADC payloads and warheads?
How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high- level view on the current state of the ADC payloads and warheads market and its likely evolution in the mid to long term.

Chapter 3 is a general introduction to ADCs and its various components, laying emphasis on the key steps involved in the manufacturing of ADCs, along with the challenges associated with supply chain and the need for outsourcing. In addition, the chapter features a detailed discussion on the need for contract manufacturing of ADC payloads and warheads.

Chapter 4 provides an overview of the current market landscape of ADC payloads and warheads, based on multiple parameters, including type of payload, type of microtubule inhibitors, DNA damaging agents and topoisomerase inhibitors. In addition, it includes information on the developer’s year of establishment, and location of headquarters and company size of the players.

Chapter 5 features profiles of players involved in the manufacturing of ADC payloads and warheads. Each profile features a brief overview of the company, location of its manufacturing facilities, financial information (if available), recent developments, and an informed future outlook.

Chapter 6 features a detailed analysis of the partnerships and collaborations that have been established since 2014, covering licensing agreements, R&D agreements, mergers / acquisitions, manufacturing and supply agreements, product development agreements, service alliance, product development and commercialization agreements, and other relevant types of deals. The chapter includes analysis based on year of partnership, type of partnership model, geographical distribution of partnering activity and most active player(s) (in terms of number of partnerships inked) in this domain.

Chapter 7 provides an analysis of the expansions that have taken place in the field of ADC payloads and warheads, since 2016. It includes information on the expansions carried out by players for enhancing their service portfolios, based on a number of parameters, including year of expansion, type of expansion (capacity expansion, facility expansion and new facility), location of facility and leading players.

Chapter 8 presents details on the funding received by players engaged in the development of ADC payloads and warheads. It also includes an analysis of the funding and investment instances that have taken place in this domain, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 9 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to ADC payloads and warheads, based on several relevant parameters, such as publication year, patent type, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 10 provides an estimate of the annual demand for ADC payloads and warheads (in grams), taking into account commercial, as well as clinical scale requirement, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

Chapter 11 is a case study on the ADC contract manufacturing market, highlighting a list of contract service providers and in-house manufacturers that are currently active in this space. The chapter includes a detailed review of the overall landscape of companies offering contract services for the manufacturing of ADCs, along with information on the type of service offered, other services offered, scale of operation (preclinical, clinical and commercial), and location of manufacturing facilities.

Chapter 12 presents a case study of ADCs that are already approved and those that are under development (clinical and preclinical), providing information on their phase of development (approved, clinical and preclinical / discovery stage), therapeutic area, line of treatment, dosing regimen, target antigen, antibody isotype, type of linker, type of payload / warhead and type of payload category. In addition, it provides a list of ADC developers, along with information on their year of establishment, company size and geography. The chapter also highlights the key players (in terms of number of drugs developed) in this industry.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the likely growth of ADCs contract manufacturing market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across [A] type of payload (microtubule inhibitors, DNA damaging agents, topoisomerase inhibitors and Others) [B] payload / warhead (maytansinoids, auristatins, camptothecins, pyrrolobenzodiazepines, calicheamicin, duocarmycin and Others), [C] type of product (clinical and commercial ADCs) and [D] key geographies (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. We have presented detailed transcripts of interviews held with Kevin Daley (Market Director, Novasep), and Floris Van Delft (Founder and Chief Scientific Officer, Synaffix).

Chapter 15 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the ADC cytotoxic payload and warhead market.

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES

1. AbbVie
2. Abzena
3. ACES Pharma
4. ADC Therapeutics
5. Advanced Proteome Therapeutics
6. Alteogen
7. Antengene
8. Aptamer Group
9. Arrowpoint Partners
10. Ash Stevens
11. Avoro Capital Advisors
12. Bain Capital Life Sciences
13. Biospring Partners
14. Bliss Biopharmaceutical
15. BOC Sciences
16. Boehringer Ingelheim
17. Boehringer Ingelheim Venture Fund
18. BrightGene Bio-Medical Technology
19. Bristol Myers Squibb
20. Cambrex
21. Cancer Research UK
22. CARBOGEN AMCIS
23. Celltrion
24. Cerbios
25. Cfm Oskar Tropitzsch
26. AGC Biologics
27. Consonance Capital Investors
28. CordenPharma
29. Cormorant Asset Management
30. Creative Biolabs
31. Daiichi Sankyo
32. DH-LT-Investments
33. dievini Hopp Biotech
34. Eisai
35. Emergence Therapeutics
36. Exelixis
37. Femtogenix
38. Formosa Laboratories
39. GamaMabs Pharma
40. GEA Pharma Systems
41. General Catalyst
42. Glycotope
43. Goodwin Biotechnology
44. Gustave Roussy
45. Heidelberg Pharma
46. Iconic Therapeutics
47. ICROM
48. IDT Biologika
49. Iksuda Therapeutics
50. ImmunoGen
51. Innovent Biologics
52. Innovate UK
53. Invus
54. IONTAS
55. Kyowa Kirin
56. LegoChem Biosciences
57. Levena Biopharma
58. LI-COR Biosciences
59. Lonza
60. MabPlex
61. MacroGenics
62. Magenta Therapeutics
63. MD Anderson Cancer Center
64. MediaPharma
65. Mersana Therapeutics
66. MilliporeSigma (Merck)
67. MImAbs
68. MINAKEM
69. Mirae Asset Capital
70. Moderna
71. MuseChem
72. Navrogen
73. NBE Therapeutics
74. NerPharMa
75. New Enterprise Associates
76. NewBio Therapeutics
77. NJ Bio
78. Novartis
79. Novasep
80. Novo Holdings
81. Permira
82. Pfizer
83. PharmaMar
84. PinotBio
85. Piramal Pharma Solutions
86. Polar Capital Biotechnology Fund
87. PPF Group
88. Premier Partners
89. Rakuten Group
90. Rakuten Medical
91. Recipharm
92. Regeneron
93. Rock Springs Capital
94. SBI Group
95. Seagen
96. SEAL INVESTMENTS
97. Shimadzu
98. SOTIO
99. Spirogen (part of AstraZeneca)
100. STA Pharmaceutical (a subsidiary WuXi AppTec)
101. Synaffix
102. Syngene
103. Synthon
104. Takeda
105. TBD-Biodiscovery
106. Telix Pharmaceuticals
107. The University of Texas at Austin
108. University of Goettingen
109. Vincerx Pharma
110. Waterstone Pharmaceuticals
111. Wellington Management
112. WuXi Biologics
113. WuXi XDC
114. Zurich School of Applied Sciences
115. Zymeworks


Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.